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AbstrACt
Objectives Physiological metabolic adaptations occur 
in the pregnant woman. These may persist postpartum 
and thereby contribute to an unfavourable cardiovascular 
disease (CVD) risk profile in parous women. The aim of 
the current study is to assess time-dependent changes of 
cardiometabolic health in parous women compared with 
nulliparous women.
Design and setting We studied data of 2459 women 
who participated in the Prevention of Renal and Vascular 
End-stage Disease study, a population-based prospective 
longitudinal cohort for assessment of CVD and renal 
disease in the general population.
Participants We selected women ≥40 years at the first 
visit, who reported no new pregnancies during the four 
follow-up visits. All women were categorised in parity 
groups, and stratified for age.
Outcome measures We compared body mass index 
(BMI), high-density lipoprotein (HDL) cholesterol, blood 
pressure as continuous measurements and as clinical 
relevant CVD risk factors among parity groups over the 
course of 6 years using generalised estimating equation 
models adjusted for age.
results The BMI was significantly higher in women para 
2 or more in all age categories: per child, the BMI was 
0.6 kg/m2 higher. corresponding with 1.5–2.0 kg weight 
gain per child. HDL cholesterol was significantly lower in 
women para 2 or more aged 40–49 and 50–59 years: per 
child, the HDL cholesterol was up to 0.09 mmol/L lower. 
Blood pressure did not differ among parity groups in any of 
the age categories.
Conclusions Higher parity is associated with higher 
BMI, lower HDL cholesterol and a higher prevalence of 
cardiovascular risk factors, which is constant over time. 
These findings warrant for prospective research assessing 
determinants of cardiometabolic health at earlier age to 
understand the role of pregnancy in the development of 
CVD in women.
IntrODuCtIOn  
Pregnancy is associated with major alterations 
to the cardiovascular system and metabolic 
profile.1–4 Increases in weight, lipid levels, 
blood plasma volume and cardiac output are 
needed to maintain a healthy, physiological 
pregnancy. Postpartum, this maternal adap-
tation reverses to its prepregnancy state, 
although several changes, (eg, increased 
body weight and hypercholesterolaemia) may 
persist for several months or longer.5 Possibly, 
these persisting changes contribute to an 
increased prevalence of metabolic syndrome 
(MetS) and an unfavourable cardiometabolic 
profile in parous women.6–8 The amount 
of gestational weight gain (GWG) affects 
postpartum weight retention.9 At long-term 
follow-up, excessive GWG is associated with 
an increased body mass index (BMI), up to a 
3–4 kg/m2 21 years after pregnancy.10–12 
Previous studies assessing the relation 
between parity and cardiometabolic health 
showed conflicting results and even the asso-
ciation between parity and obesity is ques-
tioned in some studies.13–16 Long-term effects 
have only scarcely been investigated and most 
studies had a follow-up of only 1–3 years post-
partum.17 18 A recent large cross-sectional 
strengths and limitations of this study
 ► This longitudinal cohort comprised a large, well-phe-
notyped cohort with uniform assessment of all mea-
surements during a median follow-up of 6 years.
 ► The generalised estimating equation analysis which 
was performed, allowed us to assess differences 
among groups over time, focusing on group effects.
 ► Since parity itself was not assessed in this cohort, 
we used the number of children as a proxy for the 
number of childbirths.
 ► Women para  >2 were older, less often used oral 
contraceptives and more often used antihyperten-
sive medication which might have resulted in a 
slightly different metabolic profile.
 ► Age at first delivery, interpregnancy interval and 
lactation have not been assessed in this cohort and 
therefore, adjustment of the analyses for these fac-
tors was not possible.
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study among Hispanic women in the US demonstrated 
that multiparity (ie, more than four or more than six chil-
dren) was associated with obesity, low high-density lipo-
protein (HDL) cholesterol and elevated fasting glucose, 
also after adjustment for sociodemographic and lifestyle 
factors.8 In addition, results from the cross-sectional 
Rotterdam study showed an lower HDL cholesterol and 
higher total cholesterol and glucose/insulin ratios with 
higher parity in Caucasian women at 70 years of age.6
Studies on the development of cardiovascular risk 
factors over time and the quantification of this effect per 
childbirth are conflicting. Some studies suggested a linear 
association between number of children and an unfavour-
able cardiometabolic profile, while others stated that only 
multiparity is associated with an increased cardiovascular 
disease (CVD) risk.6–8 19 20
Some studies even showed a ‘J-shaped’ association in 
which women with two children had the lowest preva-
lence of coronary heart disease.6–8
The aim of the current study was to assess time-de-
pendent changes of cardiometabolic health in parous 
women, stratified for number of children, as compared 
with nulliparous controls. This study was performed in 
a well-defined longitudinal prospective cohort study that 
primarily assessed development of CVD, albuminuria and 
renal disease.21
MethODs
Participants
The Prevention of Renal and Vascular End-stage Disease 
(PREVEND) study is a longitudinal cohort follow-up study 
for assessment of cardiovascular and renal disease in the 
general population. Details of this study have previously 
been published elsewhere.22 23 In summary, all inhabi-
tants of the city of Groningen, the Netherlands, from 
1997 to 1998 at age 28–75 years (n=85 421) were invited 
to participate. All that applied, filled out a questionnaire 
and collected a first-morning void urine sample. Preg-
nant women and subjects with type 1 diabetes mellitus 
were excluded. The urinary albumin concentration was 
assessed in a total of 40 856 (47.8%) responders. A total of 
6000 participants were enrolled out of 7768 subjects with 
a urinary albumin concentration ≥10 mg/L. In addition, 
2592 participants were enrolled out of 3394 subjects with 
a urinary albumin concentration <10 mg/L. Thereby, the 
PREVEND study was enriched by subjects with an elevated 
albumin excretion.
In total, 4301 women were enrolled in the PREVEND 
study (figure 1). For the current analysis, only women 
aged 40 years or older at the first visit and who reported 
no new pregnancies during the follow-up visits were 
included. Women who reported no children were cate-
gorised as nulliparous (n=464; 18.9%). Women who 
reported one child, two children or more than two chil-
dren, were categorised as para 1 (n=277; 11.3%), para 2 
(n=1021; 41.5%) and para >2 (n=697; 28.3%).
Patient and public involvement
No participants were involved with setting out the 
research question, developing the outcome measures or 
planning the study design. The results of study results will 
be disseminated by the newsletter and the study website.
Measurements and visits
Between 1997 and 2012, the screening visits took place 
every 2–4 years. Participants completed questionnaires 
and underwent physical examinations. Blood samples 
and 24 hours urine samples were taken. The question-
naires included questions regarding parity. Participants 
reported their number of children, which was used as a 
proxy for the number of childbirths. In addition, educa-
tion level, current alcohol use and current smoking were 
assessed in these questionnaires. Details of clinical and 
laboratory measurements have previously been described 
elsewhere.22 Prescription data from pharmacies were used 
to assess the use of antihypertensive and lipid lowering 
medication. Hypertension was defined as a systolic blood 
pressure ≥140 mm Hg and/or a diastolic blood pressure 
≥90 mm Hg or the use of blood pressure lowering medi-
cation. Type 2 diabetes mellitus (T2DM) was defined as 
a fasting plasma glucose ≥7.0 mmol/L, random sample 
plasma glucose ≥11.1 mmol/L, self-reported physician 
diagnosis of T2DM, and/or the use of glucose-lowering 
medication.24 Obesity was defined as BMI ≥30 kg/m2.
Data selection for analyses was based on a fixed time 
interval of 6 years between the visits.
Figure 1 Flowchart. PREVEND, Prevention of Renal and 
Vascular End-stage Disease.
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statistical analysis
Data were arranged per patient per visit. Continuous 
variables with a normal distribution are presented as 
mean±SD and analysed using Student’s t-test or one-way 
analysis of variance followed by Tukey post hoc analysis. 
Continuous variables with a skewed distribution were 
expressed as median with 25th–75th percentile and anal-
ysed using Mann–Whitney U-test or Kruskall Wallis. Cate-
gorical variables were analysed using Pearson χ2 test or 
Fisher’s exact test, where appropriate.
For longitudinal assessment (time factor) of the 
outcome measures among the different parity groups 
(group factor), a generalised estimating equations 
(GEE) analysis was performed, including the interaction 
term group*visit (interaction factor). All analyses were 
performed using an autoregressive correlation matrix 
structure. This assumes a variable correlation between 
measurements depending on the time between measure-
ments, as was expected in the current analysis. For GEE 
analyses of continuous dependent variables (BMI, HDL 
cholesterol and mean arterial pressure (MAP)), partic-
ipants were further stratified in three age categories 
(40–49 years old, 50–59 years old and ≥60 years old). In 
addition, we performed a stepwise correction strategy, 
correcting for age (model 1), age and education (model 
2), age and oral contraceptive use (model 3) and age, 
education and oral contraceptive use (model 4).
Data were analysed using SPSS V.22.0 (SPSS Inc.) and 
GraphPad prism V.5.01 (GraphPad Software Inc., San 
Diego, California, USA). In all analyses, a p value <0.05 
was considered statistically significant.
results
study population
Table 1 provides an overview of the baseline character-
istics of women who were nulliparous, para 1, para t2 
and para >2 at the first PREVEND visit. The mean age 
was significantly higher in women who were para >2. 
The majority of all women were Caucasian. The median 
follow-up time was 6 years in all groups. The cardio-
vascular risk profile among the parity groups differed 
significantly on BMI, blood pressure, smoking and use of 
alcohol. Unfavourable blood glucose measurements and 
cholesterol profiles were related to higher parity. The 
use of blood pressure lowering medication was higher 
in women who were para >2 compared with the other 
groups, but the use of glucose and lipid lowering medica-
tion did not differ among the groups. Women who were 
para >2 less often used oral contraceptives compared with 
women who were nulliparous, para 1 or para 2.
Cardiometabolic profile in relation to parity and age
During the 6-year study period, there was a constant, 
significant difference in BMI among the parity groups 
at all age categories (figure 2A). The BMI was higher 
with every increase of parity at all age categories: per 
child, the BMI was 0.6 kg/m2 higher, equal to 1.5–2.0 kg. 
In women para >2, the BMI was 0.7–2.0 kg/m2 higher 
compared with the other parity groups. Over time, BMI 
increased significantly in all age groups (ptime<0.001), the 
change in BMI over time was similar among all parity 
groups (pinteraction=0.662–0.947). In a stepwise correction 
model, correction for age alone and correction for age 
and oral contraceptive use did not influence the differ-
ences in BMI among parity groups at all age categories 
(see online supplementary table 1). After correction for 
age, education level and oral contraceptive use, differ-
ences among parity groups were statistically significant at 
age 50–59 and >60 years only.
The prevalence of obesity increased with increasing 
parity at entry (pfor trend<0.001) and at 6-year follow-up (pfor 
trend<0.001; figure 3). At visit 1, 15% of the nulliparous 
women was obese, compared with 26% of the women 
para >2. After the course of 6 years, this was increased to 
16% of the nulliparous women compared with 30% of the 
para >2. The increase in prevalence over time was similar 
among the groups (p=0.450). In a stepwise correction 
model, correction for age alone and correction for age 
and oral contraceptive use did not influence the differ-
ences in HDL cholesterol among parity groups at all 
age categories (see online supplementary table 1). After 
correction for age, education level and oral contraceptive 
use, differences among parity groups were not statistically 
significant anymore at all age groups.
HDL cholesterol differed among the groups, except 
for participants aged ≥60 years (figure 2B). The HDL 
cholesterol was lower with every increase of parity, except 
for participants older than 60 years: per child, the HDL 
decreased with 0.05 mmol/L. Women para 2 and women 
para >2 had significant lower HDL cholesterol at both 
measurements compared with nulliparous women aged 
40–49 years (0.08–0.12 mmol/L) and 50–59 years (0.10–
0.17 mmol/L). Over time, HDL cholesterol increased 
significantly in all age groups (ptime=0.001–0.007) and the 
change in HDL cholesterol over time was similar among 
all parity groups (pinteraction=0.163–0.530).
Low HDL cholesterol (<1.29 mmol/L) prevalence 
differed among the groups at visit 1 (pfor trend<0.001) and 
at follow-up visit (pfor trend=0.006); low HDL cholesterol 
was more common when parity increased (figure 3). Low 
HDL cholesterol prevalence inclined similar in all groups 
over time (p=0.160).
There were no differences among the parity groups 
over time in MAP at all ages, although MAP increased 
in all groups at age 40–49 years and 50–59 years and 
decreased in all groups at age ≥60 years (figure 2C). The 
change in MAP over time was similar among all parity 
groups (pinteraction=0.348–0.815). Prevalence of hyper-
tension increased with parity both at entry visit (pfor 
trend<0.001) and at follow-up (pfor trend<0.001). Hyperten-
sion prevalence increased similar in all groups over time 
by 4%–10% (p=0.761; figure 3).
Occurrence of T2DM did not differ among the groups 
at entry (pfor trend=0.094), although a positive association 
was found between T2DM prevalence and parity after 
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6 years (pfor trend=0.018). The increase in T2DM over time 
was comparable at all groups (p=0.336). T2DM preva-
lence was <10% at all groups at both visits (figure 3).
DIsCussIOn
In this longitudinal cohort study, having two children 
or more was associated with a higher BMI in all age cate-
gories and with a lower HDL cholesterol, but not with 
changes in blood pressure. A higher parity was associated 
with higher prevalence of obesity, low HDL cholesterol and 
a higher prevalence of hypertension. These associations 
were constant over time. As analyses were stratified and/or 
adjusted for age, these results suggest a direct association 
of parity itself with BMI, HDL cholesterol levels and cardio-
vascular risk factor prevalence. Other factors attributing to 
parity, that is, education and oral contraceptive use, might 
have contributed to these differences and therefore, our 
results should be interpreted with caution.
Since BMI appears to be one of the most important 
cardiometabolic risk factors, the influence of parity 
on BMI is of great interest. This strong effect of BMI 
is due to the direct effect on CVD onset and due to its 
adverse effect on lipid profile and blood pressure.25–28 
Results from a population-based cohort study among 
4699 women suggested that weight or weight chances 
might be an important mediator in the effect of parity 
on MetS, thus confirming the importance of BMI in 
regard to cardiometabolic health.19 In our study, roughly 
each extra child is associated with 1.5–2.0 kg weight gain. 
Similar, each extra child is associated with 0.05 mmol/L 
Table 1 At entry table PREVEND stratified for parity
No children
(n=464)*
One child
(n=277)*
Two children
(n=1021)*
More than two 
children (n=697)*
P 
value**
General characteristics
  Age (years) 52.2 (10.1) 52.2 (9.0) 52.3 (8.4) 56.9 (9.6) <0.001
  Follow-up time (years) 11 (11–12) 11 (11–12) 11 (11–12) 11 (11–12) 0.71
  Caucasian (n [%]) 445 (96.9%) 264 (96.4%) 995 (98.0%) 663 (95.7%) 0.04
  Job (n [%]) 315 (68.3%) 127 (47.4%) 467 (46.5%) 264 (38.6%) <0.001
Cardiovascular risk profile
  BMI (kg/m²) 24.6 (22.5–27.7) 25.3 (22.5–28.6) 25.8 (23.4–28.8) 26.9 (24.0–30.2) <0.001
  SBP (mm Hg) 120 (109–138) 121 (110–140) 122 (111–138) 130 (115–146) <0.001
  DBP (mm Hg) 71 (65–78) 71 (67–77) 71 (66–78) 73 (67–79) 0.004
  Current smoker (n [%]) 139 (30.0%) 105 (37.9%) 326 (31.9%) 195 (28.0%) 0.02
  Alcohol use (n [%]) 203 (44.0%) 137 (49.6%) 503 (49.4%) 378 (54.5%) 0.007
  Cardiovascular comorbidity (n [%]) 11 (2.4%) 11 (4.1%) 24 (2.4%) 24 (3.6%) 0.30
  Renal disease requiring dialysis (n ([%]) 1 (0.2%) 0 (0%) 3 (0.3%) 1 (0.1%) 0.78
Laboratory results
  Glucose (mmol/L) 4.6 (4.3–5.0) 4.7 (4.3–5.1) 4.7 (4.3–5.0) 4.8 (4.4–5.2) 0.002
  Insulin (mmol/L) 7.0 (4.9–10.7) 7.6 (5.1–11.5) 7.8 (5.6–11.2) 8.5 (6.0–13.4) <0.001
  HOMAir 1.4 (1.0–2.4) 1.6 (1.0–2.5) 1.6 (1.1–2.4) 1.8 (1.2–3.0) <0.001
  Total cholesterol (mmol/L) 5.7 (5.0–6.4) 5.7 (5.1–6.5) 5.8 (5.0–6.7) 6.0 (5.3–6.7) <0.001
  HDL cholesterol (mmol/L) 1.5 (1.2–1.8) 1.5 (1.2–1.8) 1.4 (1.2–1.7) 1.4 (1.2–1.7) <0.001
  Triglycerides (mmol/L) 1.0 (0.8–1.5) 1.1 (0.9–1.7) 1.1 (0.9–1.6) 1.2 (0.9–1.6) <0.001
Medication use
  Total blood pressure lowering (n [%]) 65 (16.4%) 39 (16.5%) 140 (15.6%) 151 (24.4%) <0.001
  ACEi/ARB (n [%]) 19 (4.7%) 8 (3.3%) 41 (4.5%) 44 (7.0%) 0.07
  Glucose lowering (n [%]) 7 (1.7%) 2 (0.8%) 12 (1.3%) 12 (1.9%) 0.63
  Lipid lowering (n [%]) 19 (4.7%) 15 (6.3%) 32 (3.5%) 37 (5.9%) 0.11
  Oral contraceptive use ([n %]) 79 (18.2%) 50 (19.5%) 198 (21.1%) 90 (14.6%) 0.01
Data are presented as median (25th–75th percentile) unless otherwise stated.  
*Total number that participated at visit 1 of the study, not all variables were available for each participant at baseline.
**Significant at p <0.05 
ACEi/ARB, ACE inhibitor and/or angiotensin receptor blocker; BMI, body mass index; DBP, diastolic blood pressure; HDL, high-
density lipoprotein; HOMAir, homeostatic model assessment index; PREVEND, Prevention of Renal and Vascular End-stage Disease; 
SBP, systolic blood pressure.
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decrease in HDL cholesterol, which might be the result 
of the increased BMI.
Specific BMI measures, HDL cholesterol levels and MAP 
measures differed among the three age groups. Because 
women from all different ages were seen throughout 
all screening visits, we expect this to be an effect of age 
itself, thereby reflecting the growing influence of age on 
cardiometabolic health with increasing age.
Parallel to these metabolic differences in continuous 
measurements among the groups, occurrence of several 
clinical relevant cardiovascular risk factors, such as obesity 
and hypertension, differed among the groups as well. This 
is in line with cross-sectional studies assessing metabolic 
profile in relation to the number of children.6–8 19 However, 
some studies could not confirm the relation between 
parity and metabolic health, especially after adjustment for 
Figure 2 Development over time of BMI (A), HDL cholesterol (B) and MAP (C), stratified for parity. BMI, body mass index; HDL, 
high-density lipoprotein; MAP, mean arterial pressure.
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covariates such as lifestyle.14 15 19 29 In the stepwise correc-
tion, we found no or minimal influence of age, age and 
education level or age and oral contraceptive use on our 
results. Only after full correction for age, education level 
and oral contraceptive use, the statistical significance 
among parity groups diminished. Consequently, our find-
ings should be interpreted with caution, as these factors 
and others, such as lifestyle changes following childbirth, 
might influence cardiovascular health next to parity itself.29 
Moreover, lifestyle effects of family life and the protective 
effect of lactation could explain the influence of parity on 
cardiometabolic health.30–32
Another possible explanation behind the mechanism 
of this relationship between parity and cardiovascular 
risk factors could be found in the effect of disturbances 
by pregnancy itself that continue to last postpartum. For 
example, breast feeding is associated with a lower risk 
of cardiovascular risk factors, that is, T2DM, although 
the role of breast feeding remains controversial and 
a recent meta-analysis showed no significant effect of 
breastfeeding on postpartum weight retention.33–36 
Other factors involved in the relationship between 
parity and cardiovascular risk factors might be found 
in circulation markers. An example might be found in 
the ovarian peptide hormone relaxin, produced by the 
corpus luteum or placental throughout pregnancy, has 
emerged as cardiovascular modulator involved in vasodi-
latation and inducing angiogenesis.37 38 Moreover, relaxin 
was positively associated with insulin sensitivity and lipid 
profile in women with T2DM as well.39
Previous cohort studies showed a ‘J-shaped’ association 
between parity and coronary heart disease, with lowest 
prevalence in women with two children, or stated that 
only multiparity (ie, more than four or five children) 
was associated with increased CVD risk.6–8 However, our 
results indicate a stepwise effect of parity on cardiomet-
abolic health and having two children or more than two 
children already affects BMI, HDL cholesterol levels and 
cardiovascular risk factor prevalence.
Our paper is the first study providing detailed assessment 
of cardiometabolic health development over time in rela-
tion to parity. This longitudinal study comprised a large, 
well-phenotyped cohort with uniform assessment of all 
measurements during a median follow-up of 6 years. The 
GEE analysis which was performed, allowed us to assess 
differences among groups over time, focusing on group 
effects. However, several limitations need to be discussed. 
The mean age of women para >2 was significantly higher 
than women who were nulliparous, para 1 or para 2. In addi-
tion, women para >2 less often used oral contraceptives and 
more often used antihypertensive medication. This might 
result in a slightly different metabolic profile although 
correction of the GEE-analysis for age and oral contracep-
tive use did not significantly change the results. Despite 
extensive phenotyping, age at first delivery, interpreg-
nancy interval and lactation have not been assessed in the 
PREVEND study and therefore, adjustment of the analyses 
for these factors was not possible. Since parity itself was not 
assessed in the PREVEND, we used the number of children 
as a proxy for the number of childbirths. This might lead 
to inaccurate estimates of parity numbers, as the possibility 
of surrogacy or twin pregnancies is not taken into account. 
Additionally, no information was available regarding subfer-
tility and several pregnancy complications, which leads to 
a lower number of children in these women and might 
reflect influence the cardiometabolic profile in later life as 
well. More extensive information regarding socioeconomic 
status was not measured as well, thereby it was only possible 
to correct for education but not for other socioeconomic 
factors. Lastly, prepregnancy BMI and GWG have not been 
assessed in the PREVEND study either, although their role 
on postpartum weight retention seemed limited in a recent 
publication.9 18
Figure 3 CVD risk factors at entry. 
Hypertension=blood pressure ≥140/90 mm Hg and/or 
use of antihypertensive medication; Obesity=BMI ≥30 kg/
m2; Low HDL cholesterol=HDL cholesterol<1.29 mmol/L; 
Diabetes=fasting plasma glucose ≥7.0 mmol/L, self-report 
of a physician diagnosis and/or use of glucose-lowering 
medication. =first visit; =follow up visit. BMI, body mass 
index; CVD, cardiovascular disease; HDL, high-density 
lipoprotein. 
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The PREVEND study was enriched with subjects with 
an elevated albumin excretion, which mostly results in an 
unfavourable cardiovascular risk profile compared with 
the general population. However, albuminuria did not 
significantly differ among the groups within our analyses. 
Although our findings suggest an effect of parity itself on 
metabolic parameters, it should be noted that causality 
cannot be determined in our study. Therefore, one could 
argue that the relationship is reversed, for example, 
women with higher BMI or lower HDL cholesterol are 
more fertile and therefore have more children. Prospec-
tive research assessing prepregnancy determinants of 
cardiometabolic health are warranted to further assess 
the possible causal effect of pregnancy itself.
COnClusIOn
In this longitudinal cohort study, higher parity is associ-
ated with higher BMI and lower HDL cholesterol. This 
difference among parity groups is constant over time. 
Furthermore, higher parity is associated with a higher 
prevalence of cardiovascular risk factors among the parity 
groups over time. These findings warrant for prospec-
tive research assessing determinants of cardiometabolic 
health at earlier age to understand the role of pregnancy 
and the influence of lifestyle factors in the development 
of CVD in women.
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